2026/04/20 by Hafiza Syeda Yusra Tirmizi, Syed Ibad Hasnain, Muhammad Faris +2 · 2 voices
Biochemistry, Genetics and Molecular Biology · Computer Science · Medicine · #Alzheimer's disease #Cheminformatics #Cholinesterase and Neurodegenerative Diseases #Cognition #Computational Drug Discovery Methods #Dementia #Disease #Drug #Drug discovery #Medicinal Plants and Neuroprotection #Random forest #cs.LG #q-bio.OT
paper · pdf · open access · doi:10.48550/arxiv.2604.18316
published in arXiv (Cornell University) (Cornell University)
openalex publication_date 2026/04/20 · arxiv published 2026/04/20 · openalex created_date 2026/04/22 · arxiv updated 2026/04/25 · openalex updated_date 2026/07/28
Alzheimer disease (AD) is a neurodegenerative disease that lacks specific treatment options. Natural drugs have displayed neuroprotective effects; however, their high-throughput discovery is challenging because of the expense of experimental testing.The study proposed a machine learning approach to identify the anti-dementia activity of natural compounds based on molecular descriptors obtained from cheminformatics. The study used a set of active and inactive compounds obtained from public databases like ChEMBL and PubChem. Various molecular descriptors, including molecular weight, lipophilicity (LogP), topological polar surface area (TPSA), and hydrogen bonding descriptors, were calculated with RDKit. Data preprocessing and feature selection were applied, followed by the development of several classification models (Random Forest, XGBoost, Support Vector Machines, Logistic Regression) and their evaluation based on accuracy, precision, recall, F1-score and ROC-AUC. The outcome suggests that ensemble techniques, such as Random Forest, delivered the best predictive accuracy and ROC-AUC values. This study also highlights that critical physicochemical descriptors in particular lipophilicity, molecular weight and polarity are important in driving neuroprotective activity as identified by feature importance analysis. The integrated machine learning approach shows the potential of combining natural product research and machine learning in early drug discovery for dementia. They provide a means of rapidly exploring large datasets and selecting candidates for experimental confirmation, thus minimising costs and time in the development of drugs for neurodegenerative diseases.